SeekingAlpha · Oct 31, 2026
Teva: I Still See Upside After A Massive Rally
Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals. Read more on TEVA here.
TE
NYSE · TEVA
Teva Pharmaceutical Industries Limited
Healthcare · Drug Manufacturers - Specialty & Generic
$41.91
Up+$0.59 (+1.41%)
Updated Nov 4, 2026, 4:55 PM
SID Score
6.9/10
Composite research score
Smart Money
60/100
Neutral
- Market cap
- 34.61B
- P/E ratio
- -217.43
- Dividend yield
- 0.00%
- 52-week range
- $20.11 – $43.34
- Volume
- 11.67M
- Avg. volume
- 11.34M
Price performance · TEVA
TEVA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
TEVA closed at $41.91 after 21 trading sessions, up 7.10% for the selected period.
- Last close
- $41.91
- Period change
- +7.10%
- Period low
- $39.13
- Period high
- $42.09
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $41.905 | $43.34 | $41.54 | $41.91 | 11.67M |
| Nov 2, 2026 | $41.12 | $42.00 | $40.63 | $40.70 | 10.59M |
| Oct 30, 2026 | $41.17 | $42.59 | $41.17 | $42.09 | 7.36M |
| Oct 29, 2026 | $40.14 | $41.67 | $40.01 | $41.47 | 5.23M |
| Oct 28, 2026 | $39.74 | $40.50 | $39.46 | $39.97 | 4.65M |
| Oct 27, 2026 | $39.71 | $40.86 | $39.71 | $40.39 | 5.98M |
| Oct 26, 2026 | $39.22 | $40.115 | $39.15 | $39.95 | 6.03M |
| Oct 23, 2026 | $39.75 | $39.8399 | $39.105 | $39.41 | 5.6M |
| Oct 22, 2026 | $40.20 | $40.445 | $39.58 | $40.21 | 4.07M |
| Oct 21, 2026 | $40.18 | $41.09 | $39.50 | $40.62 | 4.6M |
| Oct 20, 2026 | $41.48 | $41.59 | $40.80 | $40.85 | 4.22M |
| Oct 19, 2026 | $41.42 | $41.8792 | $41.25 | $41.31 | 3.83M |
| Oct 16, 2026 | $41.26 | $41.70 | $40.96 | $41.50 | 5.99M |
| Oct 15, 2026 | $41.30 | $41.85 | $41.03 | $41.11 | 9.41M |
| Oct 14, 2026 | $41.11 | $41.87 | $40.71 | $40.72 | 10.27M |
| Oct 13, 2026 | $41.23 | $41.65 | $40.965 | $41.25 | 6.82M |
| Oct 12, 2026 | $41.29 | $41.49 | $40.60 | $41.17 | 7.56M |
| Oct 9, 2026 | $40.22 | $42.02 | $40.12 | $41.10 | 14.82M |
| Oct 8, 2026 | $38.84 | $39.64 | $38.25 | $39.25 | 5.82M |
| Oct 7, 2026 | $38.925 | $39.39 | $38.645 | $39.18 | 3.46M |
| Oct 6, 2026 | $39.65 | $39.93 | $38.85 | $39.13 | 5.72M |
Latest TEVA news
The latest Smart Investors Daily articles mentioning TEVA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TEVA research
Overview
Company profile and research snapshot.
Company profile
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $32.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 25, 2020 | Oppenheimer | Perform | — |
| Nov 6, 2020 | BMO Capital | Market Perform | — |
| Aug 6, 2020 | SVB Leerink | Market Perform | — |
| Aug 6, 2020 | Barclays | Equal-Weight | — |
| Jul 27, 2020 | Goldman Sachs | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
Teva's pivot from generics to branded drugs has succeeded, but keep an eye out for this potential headwind.
Yahoo · Oct 29, 2026
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Yahoo · Oct 27, 2026
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adultsAcquisition adds differentiated late-stage investigational asset with potential to address a significant unmet need for patientsTransaction supports Teva’s Pivot to Growth strategy and the company’s disciplined approach to business development TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Teva Phar
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
